Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Addition by subtraction

Existing treatments for Duchenne muscular dystrophy are only palliative, and survival beyond the early 30s is rare. Prosensa B.V. believes its exon skipping technology can target the cause of the disease and halt its progression by modulating pre-mRNA processing so that a functional form of dystrophin is produced. Last month, the company published data from a pilot trial in The New England

Read the full 620 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers